Physician profile
Gary Barton
NPI 1265473821
$2,798.70
in general payments reported to CMS, 2019-2025
18 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $487 · 2020: $206 · 2021: $641 · 2022: $710 · 2023: $495 · 2024: $153 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $590 · Gift: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $590.20 |
| Gift | $163.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,237.56 | 2019-2023 | Rinvoq, Linzess, Viberzi |
| Braintree Laboratories, INC. | $396.31 | 2021-2024 | Suflave |
| Janssen Scientific Affairs, LLC | $298.03 | 2019-2022 | |
| Pfizer INC. | $236.10 | 2019-2023 | |
| Janssen Biotech, INC. | $150.89 | 2020-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $135.25 | 2019-2022 | |
| Genzyme Corporation | $83.88 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $77.66 | 2023 | Dupixent |
| Medtronic, INC. | $45.77 | 2025 | Interstim |
| Merck Sharp & Dohme LLC | $35.11 | 2021-2024 | Dificid |
| Aimmune Therapeutics, INC. | $26.47 | 2025 | Vowst |
| Celgene Corporation | $26.11 | 2021-2022 | |
| Allergan, INC. | $20.84 | 2020 | |
| Redhill Biopharma INC. | $16.91 | 2021 | |
| Gilead Sciences, INC. | $11.81 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Barton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.